Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Raltegravir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Raltegravir | DRUG | Tablet, Oral, 400 mg, twice daily for 5 Days |
| Atazanavir | DRUG | Capsule, Oral, 300 mg, twice daily for 7 Days |
| Atazanavir + Raltegravir | DRUG | Capsule/Tablet, Oral, 300/400, twice daily for 14 Days |
Inclusion Criteria: * Healthy male and female subjects between the ages of 18 to 45 years old with a body mass index (BMI) of 18 to 32 kg/m² * Prior to enrollment, subjects must have physical and laboratory test findings within normal limits, and women of childbearing potential (WOCBP) must have a ...
Top 20 of 28 competitors
Raltegravir is an investigational small molecule being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development. The drug is being evaluated in a clinical trial with healthy volunteers to assess its effects, though it has not yet been approved for any use.
Raltegravir is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this small molecule for the treatment of HIV Infections, and the drug is currently in Phase 1 development.
Raltegravir is in Phase 1 clinical development. It is an investigational drug for HIV Infections and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
Raltegravir has one completed clinical trial, NCT00518297, titled "DDI HV (ATV - Merck)". This Phase 1 study enrolled 22 participants in the United States and was an active-controlled trial involving healthy volunteers aged 18 years and older. The trial is no longer active.
Raltegravir is a distinct investigational drug being developed by Bristol-Myers Squibb Company. No alternative names for Raltegravir have been reported in the clinical trial information. It is being studied specifically for HIV Infections and is currently in Phase 1 development.